What Is Revelation Biosciences, Inc. (REVB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Revelation Biosciences, Inc. at $1.09. With an estimated intrinsic value of $2.75 and 5 of 7 models pointing higher, the average implied return is +151.9%. The most optimistic model, Dynamic NAV, places fair value at $5.50 (+404.8%), while ML-RIV — the most conservative — estimates $0.23 (-79.2%). This +484.0% gap reflects genuine analytical uncertainty about Revelation Biosciences, Inc.'s intrinsic worth.
What Do the Models Say About REVB?
7 of 13 models are currently active for REVB. Of these, 5 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates REVB's intrinsic value at $2.31, implying +111.8% upside from the current price. See which stocks rank higher →
How Does REVB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, REVB ranks #318 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a pharmaceutical industry, Revelation Biosciences, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating REVB should weigh these sector-specific dynamics alongside our model-derived fair values.
Is REVB a Value Trap?
CirclFi's Value Trap algorithm assigns REVB a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Revelation Biosciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Revelation Biosciences, Inc.'s fundamental quality profile registers 4.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +484.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every REVB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across REVB's 7 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad